Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline
24 Oct 2022
Acquisition
Preview
Source: FierceBiotech
Sumitomo has landed its takeover target. After seeing Myovant turn down its original offer, the Japanese drugmaker has added almost 20% to its price to get the deal done and snag a phase 2 in vitro fertilization asset.
Osaka-based Sumitomo became a major shareholder in Myovant in 2019 and, having seen its partner’s share price fall from above $20 to briefly below $10, made a move to buy the remaining 48% of the drug developer earlier this month. Myovant promptly knocked back the $22.75-a-share offer but left the door open to negotiations. Sumitomo returned with an offer of $27 a share and persuaded Myovant to sign.
The deal centers on two commercial products, Orgovyx and Myfembree, but will also give Sumitomo control of a pipeline prospect, MVT-602. Takeda tried and failed to develop the oligopeptide kisspeptin-1 receptor agonistkisspeptin-1 receptor agonist as a treatment for low levels of testosterone and other sex hormones.
After missing the endpoints in phase 2 trials, Takeda offloaded the rights to the drug candidate as part of the deal with Roivant Sciences that birthed Myovant. While Takeda studied the molecule, then known as TAK-448, in men with sex hormone disorders, the new partners pitched it for use in female infertility at the time of their deal in 2016.
Since then, Myovant has published phase 1 and phase 2a data on the candidate, linking it to a surge in luteinizing hormone associated with high and dose-dependent rates of ovulation. The company framed the data as evidence that MVT-602 could become a safe alternative egg-maturation trigger.
Yet the progress of, and investment in, MVT-602 has stalled. In its 2021-22 financial year, Myovant racked up $318,000 in R&D costs specific to the candidate, down from $4.9 million in 2018-19. In theory, Sumitomo, a larger company, has the resources to kick-start development, but it made no mention of the molecule in its statement to disclose the Myovant merger.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.